Paul Shaughnessy

3.9k total citations · 1 hit paper
85 papers, 1.8k citations indexed

About

Paul Shaughnessy is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Paul Shaughnessy has authored 85 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 44 papers in Oncology and 20 papers in Immunology. Recurrent topics in Paul Shaughnessy's work include Hematopoietic Stem Cell Transplantation (38 papers), CAR-T cell therapy research (27 papers) and Multiple Myeloma Research and Treatments (13 papers). Paul Shaughnessy is often cited by papers focused on Hematopoietic Stem Cell Transplantation (38 papers), CAR-T cell therapy research (27 papers) and Multiple Myeloma Research and Treatments (13 papers). Paul Shaughnessy collaborates with scholars based in United States, United Kingdom and Australia. Paul Shaughnessy's co-authors include Paul A. Carpenter, John R. Wingard, Yair Gazitt, Bipin N. Savani, Jeffrey Schriber, Corey Cutler, Paul J. Martin, Donna A. Wall, Peter Curtin and Mark R. Litzow and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paul Shaughnessy

72 papers receiving 1.7k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

2012 423 citations John R. Wingard, Bipin N. Savani et al. Biology of Blood and Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Shaughnessy United States	20	1.3k	508	494	274	269	85	1.8k
Taiga Nishihori United States	22	984 0.7×	751 1.5×	344 0.7×	390 1.4×	231 0.9×	169	1.7k
Danielle M. Townsley United States	23	1.4k 1.0×	333 0.7×	550 1.1×	457 1.7×	383 1.4×	64	2.2k
WJ Miller United States	12	1.0k 0.8×	242 0.5×	312 0.6×	272 1.0×	363 1.3×	19	1.4k
JM Rappeport United States	15	1.4k 1.1×	471 0.9×	436 0.9×	172 0.6×	390 1.4×	24	1.9k
Antonella Geromin Italy	21	641 0.5×	549 1.1×	221 0.4×	316 1.2×	179 0.7×	55	1.2k
Leonard T. Heffner United States	21	1.1k 0.8×	717 1.4×	172 0.3×	687 2.5×	299 1.1×	68	1.7k
Kavitha M. Lakshmi India	19	1.1k 0.8×	258 0.5×	137 0.3×	662 2.4×	239 0.9×	105	1.4k
Hirohito Yamazaki Japan	21	1.0k 0.8×	251 0.5×	692 1.4×	79 0.3×	240 0.9×	95	1.4k
Jorge Vela‐Ojeda Mexico	19	1.1k 0.8×	346 0.7×	259 0.5×	258 0.9×	668 2.5×	79	1.5k
M. A. Boogaerts Belgium	20	823 0.6×	242 0.5×	232 0.5×	266 1.0×	262 1.0×	29	1.2k

Countries citing papers authored by Paul Shaughnessy

Since Specialization

Citations

This map shows the geographic impact of Paul Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Shaughnessy more than expected).

Fields of papers citing papers by Paul Shaughnessy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Shaughnessy. The network helps show where Paul Shaughnessy may publish in the future.

Co-authorship network of co-authors of Paul Shaughnessy

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Shaughnessy. A scholar is included among the top collaborators of Paul Shaughnessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Shaughnessy. Paul Shaughnessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guerrero, Thomas, et al.. (2025). Late Neurotoxicity after Chimeric Antigen Receptor T Cell Therapy; The Advanced Practice Professional and Nursing Approach to Diagnosis and Management. Transplantation and Cellular Therapy. 31(2). S498–S498.

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy. 31(2). S216–S217. 1 indexed citations

Majhail, Navneet S., Minoo Battiwalla, Aravind Ramakrishnan, et al.. (2025). Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring. JCO Oncology Practice. 21(11). 1601–1608. 1 indexed citations

Martin, Casey, Betsy Blunk, Sarah T. Garber, et al.. (2025). Remote Patient Monitoring for 15 Vs. 30 Days in Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System. Transplantation and Cellular Therapy. 31(2). S223–S224.

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2024). Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. Blood. 144(Supplement 1). 963–963. 1 indexed citations

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2024). Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. Blood Advances. 9(2). 429–435. 4 indexed citations

Shah, Bijal, Jeremy Pantin, Karamjeet Sandhu, et al.. (2024). Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel). Blood. 144(Supplement 1). 4837–4837.

Martin, Casey, Betsy Blunk, Aravind Ramakrishnan, et al.. (2024). Comparison of 15- Vs. 30-Day Remote Patient Monitoring for Outpatient Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across a Large Health System. Blood. 144(Supplement 1). 2300–2300. 1 indexed citations

Ghobadi, Armin, Joseph P. McGuirk, Paul Shaughnessy, et al.. (2024). CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 144(Supplement 1). 4829–4829. 5 indexed citations

10.

Battiwalla, Minoo, Michael Tees, Ian W. Flinn, et al.. (2023). Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non-Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network. Transplantation and Cellular Therapy. 29(2). S55–S55. 2 indexed citations

11.

Munshi, Pashna N., Yue Chen, Kwang Woo Ahn, et al.. (2022). Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 28(8). 487.e1–487.e7. 11 indexed citations

12.

Vargas, Frederick Arce, Claire Roddie, Paul Shaughnessy, et al.. (2022). Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process. Transplantation and Cellular Therapy. 28(3). S201–S202. 1 indexed citations

13.

Palmer, Jeanne, Jeannine S. McCune, Miguel‐Angel Perales, et al.. (2016). Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biology of Blood and Marrow Transplantation. 22(11). 1915–1925. 110 indexed citations

14.

Bachier, Carlos, Paul Shaughnessy, César O. Freytes, et al.. (2005). Efficacy of fluconazole prophylaxis for autologous peripheral blood stem cell transplantation: Results of a prospective, randomized, controlled, multicenter, open label study. Biology of Blood and Marrow Transplantation. 11(2). 106–106. 1 indexed citations

15.

Shaughnessy, Paul, et al.. (2005). Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 11(2). 28–28. 1 indexed citations

16.

Gazitt, Yair, Paul Shaughnessy, & Qun Liu. (2001). Differential Mobilization of CD34 ⁺ Cells and Lymphoma Cells in Non-Hodgkin's Lymphoma Patients Mobilized with Different Growth Factors. Journal of Hematotherapy & Stem Cell Research. 10(1). 167–176. 21 indexed citations

17.

Gazitt, Yair, et al.. (2001). Mobilization of Dendritic Cells and NK Cells in Non-Hodgkin's Lymphoma Patients Mobilized with Different Growth Factors. Journal of Hematotherapy & Stem Cell Research. 10(1). 177–186. 25 indexed citations

18.

Gazitt, Yair, G. David Roodman, César O. Freytes, et al.. (2000). A phase I-II clinical trial with a combination of gemcitabine (GEMZAR) and paclitaxel (TAXOL) for the treatment of refractory multiple myeloma (MM) patients. Blood. 96. 3 indexed citations

19.

Shaughnessy, Paul, et al.. (2000). Correlation of CD34 ⁺ Cell Counts with Volume of Bone Marrow Collected for Allogeneic Bone Marrow Harvests. Journal of Hematotherapy & Stem Cell Research. 9(6). 891–894. 4 indexed citations

20.

Gazitt, Yair, et al.. (2000). Peripheral Blood Stem Cell Mobilization with Cyclophosphamide in Combination with G-CSF, GM-CSF, or Sequential GM-CSF/G-CSF in Non-Hodgkin's Lymphoma Patients: A Randomized Prospective Study. Journal of Hematotherapy & Stem Cell Research. 9(5). 737–748. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact